Trigger
Maven Clinic's VP of Design chair is empty. Eli Horne left after 2.5 years. The Greenhouse posting updated July 8 is his backfill. He wrote the JD. He is actively promoting it. Confidence: high. His farewell post, his personal portfolio, and the posting language all corroborate.
Window
Eleven days since the July 8 update. A cluster of design hires confirms live recruiting infrastructure: Design Lead (Consumer), Product Designer (Maternity), Senior Staff Product Designer (Care Delivery), Senior Brand Designer. All posted or updated in the last three weeks. They are building the team around an empty chair.
The prior Signal Watch flagged this role approaching the edge of its freshness window. The cluster means the hiring committee is already in motion.
What this trigger probably means for the design org
Horne built Maven's AI practice. He shipped Maven Intelligence, an AI orchestration layer for clinical care running NVIDIA NeMo Guardrails and HIPAA-compliant LLM integrations. That product went live in March 2026. Same quarter, Maven opened a direct-to-consumer channel and launched nationwide consumer care in May. The person who laid the foundation left right as the surface area doubled.
Most candidates will pitch "I can build your AI practice." The AI practice exists. It is live, in production, under clinical constraints. The mandate is governing and scaling a live AI product across two expanding surfaces. Pitch the second version.
Your angle
Narrative fit: Maven Intelligence is running. The consumer surface just doubled. The design mandate now is governing where AI stops and a clinician acts. That is the Decision Gate from your Trust essay, stated as a job requirement. Your Thermo Fisher work is the proof: five modules running across nine pharma manufacturing sites, one non-negotiable human gate (QA regulatory release), $20M+ in recovered margin, 100% partner adoption. The architectural problem is the same. AI can orchestrate care recommendations, surface follow-ups, prompt adherence. The moment a clinical decision affects a birth outcome, automation stops. A human acts with full context. You have designed that stop.
Secondary: Red Cross ($847K disbursed, 6 systems→1, national deployment). Mission-critical platform where the wrong caseworker decision carried direct human consequences. Same pattern, different domain.
Who to contact
Primary buyer: Jason Lee, Chief Product & Operating Officer. The role reports to him. He oversees design and development of Maven's virtual platform. His LinkedIn profile did not surface through public search in this pass. Use his Maven author page as the primary public profile. If you find him through your private LinkedIn graph, DM there.
Public fingerprint: Thin. No recent LinkedIn posts, podcast appearances, or bylined articles in the last six months. The strongest attributable signal is a 2021 Maven Q&A where he said trust is key to healthcare products because patients seek care when vulnerable and need to consistently get what they need. He also flagged the risk of high-growth product teams getting trapped "band-aiding across a broad surface area" when business priorities outscale systems. He is listed as speaking at Maven's Onward conference September 30. No talk title or quote is public yet.
Warm path assessment: Eli Horne is the route. He is an ADPList mentor. He wrote the JD. He is actively promoting the role. Even cold outreach to Horne is socially natural since he is explicitly backfilling himself. Check for ADPList, Stripe, Kickstarter, or Google design-community overlap in your network. Sequoia (Jess Lee on Maven's board) is a possible investor path if you have Sequoia connections. Jason Lee outreach is cold unless your private LinkedIn graph shows mutuals.
Channel: Warm intro through Horne → Jason Lee. Cold LinkedIn DM to Jason Lee only if no Horne path materializes.
Outreach messages
Subject line: The Decision Gate problem in clinical AI
Message to Horne (to initiate the warm path):
Eli — your farewell post about Maven landed with me, especially the part about writing the JD yourself. The role you described — governing where AI handles care workflows and where human judgment is irreplaceable — is the exact design problem I published a framework for earlier this year (junochen.com/trust-is-the-new-interface). I built that boundary at Thermo Fisher across nine pharma manufacturing sites. Would you be open to connecting me with Jason Lee? Happy to send context on my background first if that's useful.
Warm message (via Horne introduction to Jason Lee):
Jason — Eli Horne suggested I reach out. Maven Intelligence put a live AI orchestration layer into clinical care workflows in March, and now you're hiring the design leader to govern and scale it. That's a specific problem I've worked: at Thermo Fisher, I built a pharma supply chain platform where five modules ran continuously across nine manufacturing sites, and one human gate — QA regulatory release — was non-negotiable. I published a framework for designing exactly this boundary (junochen.com/trust-is-the-new-interface). I'd welcome 20 minutes on how you're thinking about the Decision Gate in Maven's care workflows.
Cold message (to Jason Lee):
Jason — your VP of Design posting asks for "clarity about where human judgment matters most." That is not standard design-leader language. It describes a design problem I have been solving across regulated platforms for five years. At Thermo Fisher, I built a pharma supply chain platform from zero where one human gate, batch QA release, was the only step that could not automate, across nine sites and six partners. I published a framework for designing that boundary in agentic systems (junochen.com/trust-is-the-new-interface). I am currently Head of Product at TinyFish, an enterprise web agent platform, working through agent traces, auditability, and governance challenges in production daily. With Maven Intelligence live and your consumer surface expanding, I would value 20 minutes on how you are approaching the clinical governance layer in design.
What not to say:
- Do not pitch "building an AI practice from zero." Horne already did that. Pitching the build signals you have not read the context.
- Do not surface the $300M/$425M funding discrepancy as a concern. The $125M Series F (October 2024, $1.7B valuation) explains it. The About page is stale.
The non-obvious thing
Horne wrote this job description. That fact changes how you read every line.
When a posting says "clarity about where human judgment matters most," that is a departing design leader encoding his philosophy into hiring criteria. Not a recruiter filling a template. Competing candidates will pattern-match against requirements. Respond to the philosophy. The posting is also unusually specific about AI-native practice for a healthcare company: conversational interfaces, agent-driven workflows, adaptive onboarding. That specificity comes from someone who shipped Maven Intelligence and knows what the next leader actually needs to do. Respond to the sophistication of the brief. Most candidates will see "healthcare company" and reach for their most clinical-sounding case study.
One probe question worth deploying: Maven's press releases say 2,300+ employers. The VP posting says 2,000+. Ask which number is current. It signals you have read beyond the JD, and the answer tells you whether the posting was written before recent growth or the count methodology changed.
Warning signs
Design does not appear on Maven's senior leadership page. The role reports to CPO, not CEO, though the posting says "direct line to CEO and CPO." Probe what "direct line to CEO" means operationally. Quarterly updates and weekly product reviews are different things. Horne held the VP Design title for 2.5 years without appearing on the leadership page. That could mean design is structurally embedded in product rather than elevated as a peer function. Not disqualifying. Worth understanding before you are in seat.
- Maven's Onward conference lineup: Jason Lee is listed as a speaker at Maven's September 30 Onward event, but no talk title or quote is public yet — monitor for pre-event content that reveals his current product priorities.
- Horne's design-community footprint: Eli Horne lists ADPList mentor and Adobe Design Circle Mentor experience on his LinkedIn profile, so check your ADPList, Stripe, Kickstarter, and Google design networks for a real mutual before defaulting to cold outreach.
- Maven Intelligence's clinical governance model: Fierce Healthcare reported that Maven uses automated evaluations and human review of sampled conversations to check for bias or gaps, which is the specific governance loop you'd be inheriting and scaling — read the full piece before any conversation with Jason Lee.
- Lux Capital's Deena Shakir: Shakir sits on Maven's board and her Lux Capital profile lists women's health and AI/ML as investment themes — a potential warm path if your network overlaps with Lux or her prior Google product partnerships work.